Prevalence and Treatment of Neuropathic Pain in Kidney and Liver Transplant Recipients.

OBJECTIVES Neurologic complications are common after kidney and liver transplant. Neurologic complications affect mortality and morbidity in transplant recipients, and neuropathic pain is an important symptom affecting a patient's quality of life. The aim of the present study was to provide readers with our experience regarding causes and treatment of neuropathic pain in patients undergoing kidney and liver transplant at our transplantation center. MATERIALS AND METHODS The medical data of 553 kidney transplant recipients and 258 liver transplant recipients who received transplant procedures at the Baskent University Transplantation Center between 2008 and May 2016 were retrospectively reviewed. Fifty-one patients who were examined by an expert neurologist and diagnosed with neuropathic pain on the basis of clinical, neurologic examination, and laboratory findings were included for analyses. RESULTS Among 811 transplant recipients, 51 patients (6.2%) were diagnosed with neuropathic pain. Of these, 22 were female and 38 were male patients, and 42 were kidney transplant recipients and 9 were liver transplant recipients. Causes of neuropathic pain included uremia, diabetes mellitus, ischemic peripheral arterial disease, inflammatory neuropathy, vasculitis, discopathy, postherpetic neuralgia, carpal tunnel syndrome, and multiple myeloma. Patients with symptoms too mild to affect daily life activities were treated conservatively. Plasmapheresis, gabapentin, pregabalin, alpha-lipoic acid, and duloxetine were administered as treatment modalities and medications. CONCLUSIONS Neuropathic pain was lower in our transplant recipients than in the general population. Treatment medications were effective for transplant recipients at lower doses for the management of neuropathic pain impairing quality of life than doses for the general population.

[1]  J. Iovanna,et al.  &agr;-Lipoic Acid Protects Against Ischemia-Reperfusion Injury in Simultaneous Kidney-Pancreas Transplantation , 2016, Transplantation.

[2]  R. Freeman,et al.  Predictors of improvement and progression of diabetic polyneuropathy following treatment with α-lipoic acid for 4 years in the NATHAN 1 trial. , 2016, Journal of diabetes and its complications.

[3]  G. Mour,et al.  Neurologic Complications After Kidney Transplantation. , 2015, Seminars in nephrology.

[4]  M. Haberal,et al.  Neurologic complications after liver transplant: experience at a single center. , 2015, Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation.

[5]  S. Hou,et al.  Neurologic complications in renal transplantation. , 2014, Handbook of clinical neurology.

[6]  I. I. L. Rosa,et al.  Complicaciones neurológicas en trasplantados de órgano sólido , 2013 .

[7]  E. López‐Laso,et al.  [Neurological complications in patients receiving solid organ transplants]. , 2013, Anales de pediatria.

[8]  A. Koskderelioglu,et al.  Neurologic complications of renal transplant. , 2012, Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation.

[9]  J. Ballenger Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial , 2011 .

[10]  T. Nurmikko,et al.  EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision , 2010, European journal of neurology.

[11]  M. Wulster-Radcliffe,et al.  A retrospective pooled analysis of duloxetine safety in 23 983 subjects , 2007, Current medical research and opinion.

[12]  M. Rowbotham,et al.  Duloxetine for the management of diabetic peripheral neuropathic pain: evidence-based findings from post hoc analysis of three multicenter, randomized, double-blind, placebo-controlled, parallel-group studies. , 2007, Clinical therapeutics.